Menopausal brain fog is common, and hormone therapy has neutral cognitive effects, according to Pauline M. Maki, PhD.
|Articles|February 7, 2012
Poll: What is Your Next Step?
Author(s)OBGYN.net Staff
You have a patient with recurrent vaginal candidiasis and have tried everything you can think of!
Advertisement
You have a patient with recurrent vaginal candidiasis and have tried everything you can think of, including vaginal suppositories and repeated courses of oral combined metronidazole and itraconazole. A high vaginal swab shows only candida.
Advertisement
Related to this article
Stephanie S. Faubion, MD, on choosing between fezolinetant and elinzanetant, liver monitoring, follow-up, and open questions in menopause care.
NK receptor antagonists significantly improved sleep disturbance in menopausal women at 4, 12, and 24 weeks in a meta-analysis of RCTs.
Perimenopausal women who were more physically active had significantly lower symptom burden across all domains, a study of 1808 Flo app users found.
JoAnn V. Pinkerton, MD, MSCP, reviews 4 pooled elinzanetant analyses from OASIS presented at The Menopause Society Annual Meeting 2026, spanning late perimenopause, sleep, VMS reduction, and safety.
Distress, not low libido alone, defines HSDD, which requires a biopsychosocial evaluation, according to Holly N. Thomas, MD, MS.
Perimenopausal women over-reported total sleep time by a mean of 35.3 minutes and under-reported wake time compared with Fitbit data.
Elinzanetant cut moderate-to-severe VMS frequency by ≥50% in 66.9% of US participants compared with 40.5% on placebo.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Before Pregnancy Begins: Why the Timing of Carrier Screening Matters
2
JoAnn V. Pinkerton, MD, MSCP, on elinzanetant across menopause subpopulations at TMS 2026
3
Wearables may add insight into perimenopausal sleep complaints
4
What to expect at The Menopause Society's 2026 Annual Meeting
5